Modified tPA could be effective stroke treatment without bleeding risk

July 17, 2012, Emory University

Even when its clot-dissolving powers are removed, the stroke drug tPA can still protect brain cells from the loss of oxygen and glucose induced by a stroke, researchers have discovered.

The finding suggests that a modified version of could provide benefits to patients who have experienced a stroke, without increasing the risk of bleeding.

The results will be published in the .

"We may have been giving the right medication, for the wrong reason," says senior author Manuel Yepes, MD, associate professor of neurology at Emory University School of Medicine. "tPA is more than a clot-busting drug, it functions naturally as a neuroprotectant,"

The co-first authors of the paper are postdoctoral fellows Fang Wu and Jialing Wu from the Department of Neurology, and Andrew Nicholson from the Department of Radiology and Imaging Sciences.

tPA was introduced as a treatment for in the 1990s. Doctors have debated its effectiveness and safety ever since, because it can increase the likelihood of deadly . Many people experiencing a stroke do not receive tPA because of or other contraindications.

"tPA is supposed to be administered within the first 3-4.5 hours of the onset of the stroke," Yepes says. "Otherwise there is no beneficial effect and instead there is an increase in the risk of hemorrhagic transformation."

Long before tPA ever became a drug, tPA was a protein produced by several tissues in the body, including . One of its functions is to convert the inactive protein plasminogen into the enzyme plasmin, which breaks down clots. Yepes' team has been studying tPA's additional functions beyond acting on plasminogen.

Exposing from the to tPA protects the neurons from dying after being deprived of oxygen and glucose, the researchers found. tPA appears to induce a set of proteins that helps cells deal with the and glucose that come from an interruption of blood flow.

This result contradicts previous reports about tPA's effects in the nervous system, some of which concluded that it can act as a neurotoxin.

"The discrepancy could be a matter of experimental design or dose," Yepes says. "Our results do suggest that the dose of tPA that is needed for a neuroprotective effect is significantly lower that the dose that we give to destroy the clot in our stroke patients."

A mutated form of tPA that could not activate plasminogen still had the protective effect on neurons in culture. Yepes' team also studied the effects of the mutated form of tPA in living animals. In mice, the researchers blocked a vessel supplying blood to the brain for one hour, simulating a stroke. Treatment with both regular and modified tPA could reduce the size of the damaged area of the brain.

The possibility that tPA may be working as a neuroprotectant also may explain why, clinically, tPA's benefits are sometimes not observed until several weeks after treatment as it has been demonstrated in large clinical studies, Yepes says.

"If it was just a matter of the clot, getting rid of the clot should make the patient better quickly," he says. "It's been difficult to explain why you should have to wait three months to see a benefit."

"One of the main implications of our finding is that a form of tPA that does not act on plasminogen could still provide benefits, without the risks of inducing a bleeding in the brain," Yepes says. "The risk of bleeding creates a lot of anxiety, and it has resulted in the regrettable fact that only a small number of patients currently benefit from treatment with tPA."

Yepes says a next step would be to try a "protease-inactive" version of tPA in a pilot clinical trial.

Explore further: Clot-busting drug safe for stroke patients taking blood thinner

More information: F. Wu et al. Tissue-type plasminogen activator regulates the neuronal uptake of glucose in the ischemic brain. J. Neurosci (2012).

Related Stories

Clot-busting drug safe for stroke patients taking blood thinner

May 10, 2012
Acute ischemic stroke patients taking the blood thinner warfarin can be treated safely with the clot-busting drug tissue plasminogen activator (tPA), according to research presented at the American Heart Association's Quality ...

Hypothermia protects the brain against damage during stroke

March 6, 2012
Thromboembolic stroke, caused by a blood clot in the brain, results in damage to the parts of the brain starved of oxygen. Breaking up the clot with tissue plasminogen activator (tPA) reduces the amount of damage, however, ...

New clue to brain bleeding after stroke treatment

October 17, 2011
The only medication currently approved for stroke treatment – tissue plasminogen activator (tPA), which dissolves blood clots – is associated with an increased risk of bleeding in the brain, particularly among patients ...

Recommended for you

Research reveals atomic-level changes in ALS-linked protein

January 18, 2018
For the first time, researchers have described atom-by-atom changes in a family of proteins linked to amyotrophic lateral sclerosis (ALS), a group of brain disorders known as frontotemporal dementia and degenerative diseases ...

Fragile X finding shows normal neurons that interact poorly

January 18, 2018
Neurons in mice afflicted with the genetic defect that causes Fragile X syndrome (FXS) appear similar to those in healthy mice, but these neurons fail to interact normally, resulting in the long-known cognitive impairments, ...

How your brain remembers what you had for dinner last night

January 17, 2018
Confirming earlier computational models, researchers at University of California San Diego and UC San Diego School of Medicine, with colleagues in Arizona and Louisiana, report that episodic memories are encoded in the hippocampus ...

Recording a thought's fleeting trip through the brain

January 17, 2018
University of California, Berkeley neuroscientists have tracked the progress of a thought through the brain, showing clearly how the prefrontal cortex at the front of the brain coordinates activity to help us act in response ...

Midbrain 'start neurons' control whether we walk or run

January 17, 2018
Locomotion comprises the most fundamental movements we perform. It is a complex sequence from initiating the first step, to stopping when we reach our goal. At the same time, locomotion is executed at different speeds to ...

Miles Davis is not Mozart: The brains of jazz and classical pianists work differently

January 16, 2018
Keith Jarret, world-famous jazz pianist, once answered in an interview when asked if he would ever be interested in doing a concert where he would play both jazz and classical music: "No, that's hilarious. [...] It's like ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.